COMP <GO>
SMTI vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Sanara MedTech Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SMTI 4
— JNJ 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $32.92 (+0.11%) • MKT CAP: $302.4M
roic
16.30%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMTI VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMTI | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.70% | 67.90% | +24.80 | SMTI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 16.30% | 25.50% | -9.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.5x | 18.5x | +11.00 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 0.71% | 2.97% | -2.26 | JNJ | /fcf-yield <GO> |
| Operating Margin | 7.10% | 34.70% | -27.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 36.40% | 28.50% | +7.90 | SMTI | /net-margins <GO> |
| Revenue Growth (YoY) | 19.00% | 6.00% | +13.00 | SMTI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.25 | 5.59 | -2.34 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.3 | 62.1 | -34.76 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.8x | 23.0x | -16.20 | SMTI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $302.4M | $662.49B | -$662.19B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMTI REV | JNJ REV | SMTI GROSS % | JNJ GROSS % | SMTI FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $103.1M | $94.19B | 92.7% | 67.9% | $2.2M | $19.70B |
| FY 2024 | $86.7M | $88.82B | 90.6% | 69.1% | -$229.6K | $19.84B |
| FY 2023 | $65.0M | $85.16B | — | — | -$3.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMTI // BETA —
JNJ // BETA 1.08